Drug Profile
DRGT 56
Alternative Names: DRGT-56Latest Information Update: 28 Apr 2022
Price :
$50
*
At a glance
- Originator Druggability Technologies
- Developer Tavanta Therapeutics
- Class Antifibrotics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Cystic fibrosis
Most Recent Events
- 28 Apr 2022 No recent reports of development identified for preclinical development in Cystic-fibrosis in Ireland
- 01 Sep 2020 Druggability Technologies is now called Tavanta Therapeutics
- 01 Apr 2020 DRGT 56 is still in preclinical trials for Cystic fibrosis in Ireland (Druggability Technologies pipeline, March 2020)